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Abstract  
Intravesical Bacillus Calmette-Guérin (BCG) immunotherapy is used for preserving the 
bladder after resection of high-risk non-muscle invasive bladder cancer (NMIBC). 
Unfortunately, to date, treatment failure, which carries a high risk of disease progression 
and occurs in about 30% of patients, cannot be predicted a priori with a simple, reliable 
test. To address this shortcoming, we examined the in vitro tuberculin-responsiveness of 
CD4 T-cells prior to the first and second rounds of BCG immunotherapy in n=42 patients 
with high-risk NMIBC. The frequencies of overnight tuberculin-activated cytokine-
expressing CD4 T-cells and their polyfunctionality were assessed by flow-cytometry; the 
levels of overnight tuberculin-induced, secreted mediators were measured by electro-
chemiluminescence. The primary endpoint was recurrence-free survival at 6 months. 
Surprisingly, tuberculin-induced, secreted IL-2 before induction therapy performed best. A 
lower cut-off at 250pg/ml provided 79% sensitivity, 86% specificity (AUC=0.852, p=0.000), 
and overall correct classification in 78.6% of cases; also, in 50% of patients later 
experiencing recurrence but none of the recurrence-free survivors it was below 120pg/ml. 
Several other parameters performed well, too, including secreted IFN- (AUC=0.796, 
p=0.002) and the frequencies of TNF-producing (TNF+) CD4 T-cells (AUC 0.745, p=0.010). 
Interestingly, higher levels of ‘polyfunctional’ CD4 T-cells (IFN-+/IL-2+/TNF+) were 
significantly associated with recurrence-free survival (AUC 0.801, p=0.002). In conclusion, 
our work shows that overnight in vitro tuberculin-induced IL-2 secretion has significant 
potential for predicting the outcome of BCG immunotherapy and may identify 50% of BCG 
failures with 100% specificity before induction therapy is begun. This should, in future, help 
doctors and patients make the best treatment choice.  
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Synopsis 
BCG immunotherapy helps preserving the bladder after removing certain bladder cancers 
but fails in about 30% of patients. A novel test identifies a priori those most likely to fail so 
they may receive other, more effective treatments. (37 words) 
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Introduction 
Bladder cancer is the ninth most frequently diagnosed cancer worldwide with an estimated 
430,000 incident cases and 165,000 deaths in 2012 (1). The incidence is highest in Western 
and Southern Europe and North America and higher in men than in women. Transitional 
cell carcinoma (TCC) accounts for over 90% of cases, the majority of which present with 
early non-muscle invasive bladder cancer (NMIBC) and are treated with transurethral 
resection. Intravesical Bacille Calmette-Guérin (BCG) immunotherapy (henceforth referred 
to as ‘BCG immunotherapy’) administered in several cycles over one year is the standard 
treatment for high-risk NMIBC and significantly reduces the otherwise high recurrence 
rates (2-5). Non-responders to BCG immunotherapy have a high risk of disease progression 
and death (6,7), however, reliable predictors of treatment outcome at baseline, i.e. prior to 
therapy induction, or early into therapy have not been identified yet.  
BCG has been administered intradermally as a tuberculosis (TB) vaccine for almost 100 
years (8). It prevents the most severe complications of TB in children (such as meningitis) in 
about 80% of cases but is less effective in preventing pulmonary TB (9). The induction of 
CD4 T-cells specific for mycobacterial antigens, in particular those producing IFN-is 
believed to explain the protective effect of the vaccine (10), however, the immunological 
correlates of protection from TB are still not well understood (11). The mechanisms by 
which anti-mycobacterial immunity induced by BCG might help contain bladder cancer are 
even less well understood. Various features of BCG-induced immune responsiveness, such 
as urinary cytokines before and at various time points following induction therapy, natural 
killer cell activity, or changes in anti-Mycobacterium bovis heat shock protein 60 (HSP60) 
antibody levels (12-19), have in the past been associated with treatment success for 
NMIBC.  Fewer studies, however, have explored specific cellular parameters. 
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Interestingly, Elsasser et al. showed that intravesical BCG increases the numbers of 
tuberculin-specific CD4 T cells detectable in blood, however, their attempt to predict the 
outcome of BCG immunotherapy based on these changes in a small study (n=18) with 
variable pathology was unsuccessful (20). The study presented here was larger (n=42), 
focused on early outcome predictors in patients with high-risk NMIBC, and included 
tuberculin-induced secreted cytokines in addition. Unlike Elsasser et al, we found strong 
associations between tuberculin-induced CD4 T-cell responsiveness and the absence of 
tumor recurrence. Our results suggest that a functional, T-cell response-based test for 
predicting BCG immunotherapy outcome is within reach and should enable individuals with 
only a small chance of success to receive more effective treatment both in terms of 
outcome and cost. 
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Materials and Methods 
 
Ethical Approval 
This study was approved by the UK Research Ethics Service (RES), City Road and Hampstead 
Research Ethics Committee, reference number 11/LO/2039. All patients gave written 
informed consent. The study was carried out in agreement with the Declaration of Helsinki.  
 
Participants 
Patients presenting at our center with high-risk NMIBC initially underwent transurethral 
resection of the tumour (TURBT). Those eligible for intravesical BCG treatment were invited 
to participate in the study. All patients followed a routine BCG (12.5mg intravesical 
OncoTICE®, Organon, N.V., USA) treatment schedule over 1 year, beginning with a 6 week-
long BCG induction course consisting of weekly instillations, then further maintenance 
boosters of 3 weekly instillations in months 4,7, and 10 (Supplementary Figure S1). A 
cystoscopy with biopsies was carried out under general anesthesia 6 weeks after each 
treatment course. Recurrence was confirmed by the presence of transitional cell carcinoma 
(TCC) in histology. The presence of TCC at 6 months was considered BCG immunotherapy 
failure. Patient characteristics are shown in Table 1. Urine samples were collected 
immediately prior to induction therapy and 4 hours after the 6th instillation. Blood samples 
were taken immediately prior to the induction and the first maintenance course. N=24 
patients had a history of BCG vaccination and/or showed a BCG vaccination scar. The 
remaining n=18 patients had no known history of BCG vaccination and no vaccination scar. 
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Blood and urine samples 
15 ml of venous blood was drawn into sodium heparin-coated collection tubes (BD 
Vacutainer) and analyzed immediately. Urine samples were collected in plain sterile 
universal containers (Sarstedt, Germany) and frozen at -80°C until analysis.  
 
PBMC preparation and activation 
Peripheral blood mononuclear cells (PBMC) were prepared using standard Ficoll-Hypaque 
(Amersham Pharmacia Biotech, Uppsala, Sweden) density gradient centrifugation as 
described in detail elsewhere (21). PBMC were washed twice and resuspended in RPMI 
1640 media containing 10% heat-inactivated fetal-calf-serum (FCS), 2 mM L-glutamine, and 
100 IU of penicillin/streptomycin (all Biochrome) (‘complete media’) at a concentration of 5 
x 106 cells per ml. Tuberculin (purified protein derivative, ‘PPD’, Statens Serum Institute, 
Copenhagen, Denmark) was dissolved in dimethyl-sulfoxide (DMSO, Fisher Scientific, 
Waltham, MA) to a final concentration of 1 mg/ml. Tuberculin was used instead of BCG to 
stimulate T-cells, since it is the most widely used mycobacterial antigen preparation for 
human testing and would be easier to standardize and handle in a routine test setting. 
Staphylococcus enterotoxin B (SEB, Sigma-Aldrich, St. Louis, MO) was dissolved in DMSO 
with a final concentration of 0.5 mg/ml. For antigen-specific stimulation, 10 µl of tuberculin 
solution in 90 µl of complete media or alternatively, 2 µl of SEB solution in 98 µl of 
complete media (positive stimulation control) was added to 400µl of cell suspension (1 x 
106 PBMC cells). The negative control contained an equivalent amount of DMSO only. The 
final assay volume was 500µl for the first 2 hours of incubation (standard incubator, 
humidified 5% CO2 atmosphere). At 2 hours, 10µg of Brefeldin A (Sigma), was added in 
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500µl of complete media (10µg/ml final concentration) bringing the final assay volume to 
1000µl. After 16 hours (total incubation time) in a standard incubator (37°C, humidified 5% 
CO2 atmosphere), cells were washed and surface-stained with fluorescence-conjugated 
monoclonal antibodies for 30 minutes at 4°C. After a further wash, pellets were treated 
with BD Lyse and BD Perm 2 buffers according to the manufacturers instructions (BD 
Biosciences, Oxford, UK). Cells were then stained intracellularly for 30 minutes at 4°C, 
washed, and re-fixed in PBS containing 0.5% paraformaldehyde prior to acquisition on a BD 
LSR II flow-cytometer (BD). 
 
Monoclonal antibodies for flow-cytometry 
The following fluorochrome-conjugated monoclonal antibodies were used for identifying 
and enumerating activated T-cells; anti-IL-2-Fluorescein isothiocyanate (FITC), anti-IFN--
Phycoerythrin-Cyanine 7 (PE-Cy7) and anti-TNF-Alexa Fluor 700 (Alexa700) (all BD 
Biosciences, San Jose, CA, USA); anti-CD40L-Brilliant violet 421 (BV421), anti-CD3-Brilliant 
violet 571 (BV571), anti-IL17A-Alexa Fluor 647 (AF647), anti-CD4-Peridinin-Chlorophyll-
protein (PerCP) (all Biolegend). Fixable Aqua stain from Invitrogen (Paisley, UK) was used to 
discriminate between live and dead cells.   
 
Flow-cytometry 
Fluorescence Minus One (FMO) controls were used to validate panels. Positive responses 
(SEB, tuberculin) were corrected for cytokine-producing cells in negative control samples 
(subtraction, subset by subset). The gating strategy is shown in Supplementary Figure S2. 
FlowJo v8 and v9 (Treestar, OR, USA) were used for flowcytometry data analysis. T-cell 
polyfunctionality was visualized using SPICE software (22). Cytometer performance was 
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ascertained daily (CS&T beads, BD), rainbow calibration beads (Spherotech, Illinois, USA) 
were used to adjust photomultiplier (PMT) voltages before each run to ascertain 
longitudinal comparability between measurements.  
 
Secreted cytokines post tuberculin stimulation  
PBMCs (1 x 106 cells) were stimulated overnight (16h) in 500 µl of complete cell culture 
media with 5µg tuberculin (10 µg/ml end concentration) (standard incubator). Tubes were 
centrifuged briefly and supernatants collected and stored at -80°C. Cytokines were 
measured using the MSD Quickplex SQ 120 platform (Meso-Scale Discovery, Maryland, 
USA) including IFN-, IL-2 and TNF, as well as IL-1β, IL-4, IL-6, IL-8, IL-10, IL-12p70 and IL-13.  
 
Statistical analysis 
Statistical analysis was performed using the SPSS 23 (IBM, New York, USA) software 
package. Non-parametric tests were used to compare cell subset frequencies between 
groups. Where appropriate, non-normally distributed variables were log-transformed to 
improve normality for logistic regression analysis. The significance threshold was set at p 
=0.05. Multiple end-point correction (Bonferroni) was applied by adjusting the significance 
threshold 0.05/n where n is the number of tested end-points.   
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Results 
Forty-two patients were recruited to the study, all of which completed BCG induction 
treatment. Six weeks after the first maintenance course, i.e. 6 months into therapy, 
recurrence was detected by histology in n=12 patients. A majority of these patients had 
already shown recurrence at the previous biopsy (6 weeks after the induction course) but 
completed another cycle of immunotherapy (Supplementary Fig. S3A). Two of these 
patients, however, underwent cystectomy (their histology had shown G3pT1 
and multifocal G2pTa, “high grade” tumours). No recurrences occurred later than 6 
months; the follow-up time ranged from 15 to 33 months (median 23 months). Since 
recurrence at 6 months is frequently used to identify BCG failure (23), patients were 
divided into two groups, identified by recurrence-free survival at 6 months (n=28, referred 
to as ‘no recurrence’ in figures/tables), or presence of tumor recurrence at 6 month (n=14, 
referred to as ‘recurrence’). There were no significant differences between the two groups 
in regards to tumor stage, presence of carcinoma in situ (CIS), disease focality, or BCG 
vaccination history (Table 2).  
 
The levels of tuberculin-inducible cytokines at baseline are a good predictor of 
recurrence-free survival at 6 months 
As a first line of investigation, we compared tuberculin-induced in vitro expression of the 
classic T-cell cytokines, IFN-, IL-2 and TNF, between the two groups, since the expression 
profiles of these cytokines in CD4 T-cells have been linked to protective anti-mycobacterial 
immunity (24,25). After overnight incubation with tuberculin, cytokine expression was 
assessed in two ways, first by enumerating cytokine-producing CD4 T-cells (Fig. 1A), and 
second, by measuring secreted cytokines in cell-culture supernatants (Fig. 1B). Individuals 
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who were free from tumor recurrence at 6 months had both higher frequencies of IFN--
producing (IFN-) CD4 T-cells and higher levels of secreted IFN- prior to induction 
treatment. With respect to discriminating the two groups, secreted IFN- (AUC= 0.796, 
p=0.002, 95%CI for AUC: 0.654 – 0.938) performed better that the percentage of IFN-+ 
CD4 T-cells (AUC=0.714, p=0.025, 95%CI for AUC: 0.555 – 0.874). While the frequencies of 
IL-2 producing (IL-2+) CD4 T-cells (AUC=0.721, p=0.021, 95%CI for AUC: 0.520-0.922) 
performed less well than those of IFN-+ CD4 T-cells, secreted IL-2 performed better than 
any of the other parameters (AUC=0.852, p=0.000; 95% CI for AUC: 0.715-0.989). TNF 
expression performed well with respect to cytokine-producing (TNF+) CD4 T-cells 
(AUC=0.745, p=0.010, 95% CI for AUC: 0.590 – 0.900) but secreted TNF was not a good 
discriminator between the groups (Fig. 1A-D). The frequencies of tuberculin-inducible CD4 
T-cells producing IL-17 or up-regulating CD154 showed no significant differences between 
the outcome groups (Fig. 1E). None of the other soluble mediators showed a significant 
difference between the outcome groups.  
 
Following induction therapy, differences between recurrence-free patients and those 
with recurrence become blurred  
The frequencies of IFN-+ CD4 T-cells showed an increase in some patients but a drop in 
others compared to baseline but the differences between the groups remained statistically 
significant (Fig. 2 A). However, neither tuberculin-induced secreted IFN-, nor any of the 
other measured parameters (secreted or cellular) were significantly different between the 
groups at that time. In addition, we found no significant difference between the groups in 
regards to changes in any of the measured parameters between baseline and 8 weeks after 
BCG induction therapy.  
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Age was not significantly associated with the outcome of BCG immunotherapy 
While it was previously reported that patient age is positively associated with recurrences 
after BCG therapy (26), we were unable to confirm a strong link with age in our study. ROC 
analysis indicated that age was not a good discriminator between the outcome groups (Fig. 
2B). Interestingly, there was weak, negative correlation between age and secreted IL-2 (not 
statistically significant) and a weak to moderate, negative correlation between age and 
secreted IFN- (p=0.022) (Fig. 2C), indicating that age might indirectly contribute to 
recurrence via reduced cytokine secretion. In order to determine more precisely the 
relative, direct effects of age and secreted cytokines on recurrence-free survival, we 
performed linear regression analysis. Since tuberculin-induced, secreted IFN- and IL-2 
were highly correlated (RS=0.743, p=0.000), but secreted IL-2 provided better 
discrimination between the outcome groups, secreted IL-2 and patient age were included 
as covariates in the model (Table 3). The model showed a significant effect of secreted IL-2 
but not patient age on recurrence-free survival and provided correct patient classification 
in 78.6% of cases.  
 
Tuberculin-induced IL-2 secretion identifies half of all BCG failures before induction 
All patients with tuberculin-inducible IL-2 <120 pg/ml (n=7) experienced recurrence, 
representing 50% of all BCG failures (Figure 2D). In contrast to this, all Individuals with a 
tuberculin-inducible IFN- >20,000 pg/ml (n=7) were recurrence-free at 6 months and for 
the rest of the follow-up time, corresponding to 25% of all recurrence-free survivors. 
Alternatively, a cut-off for IL-2 secretion at 250 pg/ml, for example, would have correctly 
classified 21/28 recurrence-free survivors (75%) and 12/14 cases with recurrence (86%), 
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providing overall correctly classification in 33/42 patients (78.6%), in agreement with the 
logistic regression analysis above (Figure 2D and Supplementary Figure S3B).  
 
BCG vaccination history had no significant effect on outcome or tuberculin response  
There was no difference between BCG-vaccinated and non BCG-vaccinated participants 
regarding outcome (Table 2). Also, neither the levels of secreted cytokines nor the 
frequencies of cytokine-positive cells following tuberculin-stimulation were significantly 
different between the two groups. There was a slight but non-significant trend suggesting 
that those with a history of BCG vaccination showed higher tuberculin-inducible levels of 
secreted IFN- and IFN-+ CD4 T-cells prior to induction therapy (Supplementary Fig. S4). 
 
Polyfunctional CD4 T-cells are associated with recurrence-free survival 
Using Boolean logic, tuberculin-activated T-cell populations producing several cytokines 
were divided into defined, non-overlapping functional subsets producing, for example, any 
one of the cytokines but none of the others, or two specific ones but none of the others, 
etc. T-cells producing several cytokines simultaneously are often referred to as 
‘polyfunctional’, a property that is thought to be relevant for protection in some infection 
models (27). Based on IFN-, IL-2, and TNF seven functional subsets can be defined (an 
eighth subset has none of the functions and is not considered). The most polyfunctional T-
cells expressing IFN-, IL-2 and TNF were significantly increased in patients who were 
recurrence-free at 6 months (p=0.001), however, several additional subsets providing 
discrimination between the groups were identified (Fig. 3A). Interestingly, these included 
two effector subsets that were negative for IL-17. Overall the best discrimination was 
provided by two subsets, one producing IFN-, TNF, and IL-2 (AUC= 0.801, p=0.002, 95%CI 
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for AUC: 0.661 – 0.941), and the other one IFN- and TNF, but not IL-17 (AUC= 0.802, 
p=0.002, 95%CI for AUC: 0.673 – 0.932) (Fig. 3B). All possible subsets based on IFN-, TNF, 
and IL-2 or IL17 are shown in Supplementary Figs. S5 and S6.  
 
Urine cytokine levels and their changes were not predictive of immunotherapy outcome  
Prior to treatment, the T-cell cytokines IL-2, IL-4, IFN-, and TNF-alpha were undetectable 
in the vast majority of urine samples. IL-6 and IL-8, by contrast were detected in all but two 
and all but 1 of the pre-treatment samples, respectively. The remaining cytokines were 
detected less consistently. Following induction treatment, however, all cytokines were 
detected in >85% of individuals. However, neither pre-treatment nor post-treatment levels, 
nor the change between the two time points was statistically different between the 
outcome groups (Supplementary Table S1).  
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Discussion 
The analysis of CD4 T-cell functions prior to BCG immunotherapy revealed several 
promising parameters showing significant differences between patients with and without 
tumor recurrence at 6 months. Because of the importance attributed to IFN- in TB 
infection and its central role in laboratory tests for latent TB (10,28) we hypothesized that 
this effector cytokine would also be of particular interest for predicting BCG 
immunotherapy outcome. Indeed, both the number of IFN-+ CD4 T cells and the levels of 
secreted IFN- after overnight stimulation with tuberculin were significantly higher in 
recurrence-free survivors. However, tuberculin-induced IL-2 secretion provided even better 
discrimination between the groups with an AUC of 0.852 (p=0.000, 95% CI: 0.715-0.989). It 
is an equally important finding that prior to induction therapy it was below a threshold of 
120pg/ml in 50% of patients with recurrence but none of the recurrence-free survivors, 
since a clinical test based on this threshold could potentially spare half of the patients with 
predicted BCG failure the experience of undergoing ultimately unsuccessful 
immunotherapy.  
The diagnostic potential of in vitro tuberculin-induced IL-2 secretion was also impressive in 
regards to predicting therapeutic success. To date, there is no other test available providing 
similar sensitivity and specificity in regards to predicting BCG immunotherapy outcome 
before induction is even begun. The levels of tuberculin-induced secreted mediators or 
cellular parameters 8 weeks after induction therapy (expect IFN-+ CD4 T-cells), or their 
changes compared to baseline were not useful for predicting BCG immunotherapy 
outcome. This seems to confirm the results by Elsasser et al.(20). At any rate, a test that 
predicts the outcome after induction therapy will be less useful than a test that predicts 
the outcome beforehand.  
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When BCG immunotherapy became the gold standard treatment for preserving the 
bladder after resection of high grade NMIBC about three decades ago, the mechanisms of 
protection were unclear. Its success was often attributed to generally augmented immune 
responsiveness and in particular the innate immune system (29,30).  
NK-cells, which are part of the innate immune system, are of particular interest in regards 
to killing bladder tumor cells (31). Alternative depletion of NK-cell and T-cell populations 
from BCG-stimulated, human mononuclear cell suspensions indicated that the substantial 
cytotoxic effect of such suspensions against bladder tumors was mostly explained by NK-
cells (32). Also, mice depleted of NK-cells or NK-cell deficient mice had no benefit from BCG 
immunotherapy in a syngeneic, orthotopic murine bladder cancer model (32). Others have 
confirmed a critical role of NK cells in mediating the effects of BCG immunotherapy and 
suggested that infection of bladder cancer cells with BCG may be essential for this 
mechanism (33).  
However, many publications also pointed to a role of adaptive immunity. For example, it 
was shown that lymphocytes in the urine of patients after intravesical BCG are for the most 
part CD4 T-cells (34), and that BCG induced lymphocyte proliferation was higher in 
recurrence-free survivors compared to individuals with recurrence (n=10) (35). Mouse 
models showed that bladder mucosa-infiltrating T-cells following intravesical BCG were 
predominantly CD4 T-cells (36) and that T-cells were required for effective BCG 
immunotherapy (37). More recently it was reported that prior parenteral exposure to BCG 
increased the effect of BCG immunotherapy in mice and that patients with a positive 
tuberculin skin test (TST) response have better recurrence-free survival rates (38).  
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However, despite their obvious role in the response to BCG immunotherapy, the effect of 
CD4 T-cells may be indirect, for example via IFN--mediated natural killer(NK)-cell 
activation. Of note, the cytotoxic potential of BCG-induced NK cells can be enhanced by 
IL‑12 and IFN- (39) and CD4 T-cells are a major source of IFN- in TB infection. Whereas 
NK-cells may ultimately kill the tumor cells, memory CD4 T-cells boosted by BCG are likely 
to facilitate their action.  This is one plausible explanation, why an in vitro CD4 T-cell 
activation assay can predict BCG immunotherapy outcome.   
 
The reason why cytokine responses (both secreted and intracellular) were not significantly 
higher in participants with a known history of BCG vaccination compared to those without, 
is probably that a majority of the older individuals in our study were exposed to 
mycobacterial antigens (other than the BCG vaccine) in the past. This will include exposure 
to TB during and after World War II but also nontuberculous mycobacteria, which, likewise, 
will cause tuberculin responsiveness (40)(41). Like the TST, our test measures previous 
exposure, but provides a better quantitative measure of tuberculin sensitization, and 
apparently, better prediction of BCG immunotherapy success compared to the TST (38).  
 
While several studies identified significant differences between patients with recurrence 
and recurrence-free survivors in regards to a number of parameters (cytokines in blood or 
urine, patient and/or tumor-related characteristics such as age, sex, tumor stage, 
carcinoma in situ, etc.) these were too subtle to effectively inform treatment choice (26,42-
49). Our study was probably too small to confirm any of these differences but conversely, 
did not have sufficient power to detect their absence.  
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In this study, the analysis of cytokine levels in urine did not discriminate between the 
outcome groups, neither at baseline nor after the last dose of induction treatment. 
However, a promising approach to predicting BCG immunotherapy outcome was recently 
presented by Kamat et al. who developed an algorithm based on a number of clinical 
characteristics and in addition the changes of a panel of 12 cytokines measured in urine at 
6 weeks (last dose of induction course) and at the time of the third dose of the first 
maintenance course (50). This approach, which effectively includes a functional in vivo test, 
provided an AUC of 0.855 (ROC-analysis) for discriminating recurrence from recurrence-
free survival and was termed ‘CyPRIT’. Since our cytokine panel included different 
cytokines and our study was smaller, we did not try and emulate this approach. Of note, 
overnight tuberculin-induced secretion of IL-2 in our study provided similarly good 
discrimination between outcome groups (AUC 0.852) as the CyPRIT method. It should be 
tested in larger studies as soon as possible to see if it is as robust as CyPRIT. Also, 
tuberculin-induced secreted IL-2 provided good outcome prediction prior to BCG 
immunotherapy, which in a clinical setting would be a massive advantage over tests not 
predicting outcome until the end of the induction therapy. 
 
In regards to functional subsets of T-cells, those that produce IFN-, TNF, and IL-2 
simultaneously (‘polyfunctional’) were previously associated with protection in vaccine 
models (27) and, interestingly, this subset was significantly increased in recurrence-free 
survivors prior to BCG immunotherapy. One possible reason for this might be that T-cells 
producing several cytokines at the same time also produce higher levels of each (21). 
However, overall, intracellular markers relating to T-cell polyfunctionality showed 
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considerable promise to be developed into clinical markers, but would be more complex to 
measure than secreted cytokines or single cytokine-positive CD4 T-cells. 
 
Conclusions 
Our pilot study shows that the in vitro tuberculin-responsiveness of CD4 T-cells prior to 
BCG immunotherapy is a promising outcome predictor. It measures the ability of the 
adaptive immune system to mobilize an effective immune response to BCG, however, it 
remains unclear what the involvement of CD4 T-cells is in the actual anti-tumor response. It 
is an advantage of our approach that T-cell activation assays based on overnight tuberculin 
stimulation are easy to standardize; similar tests already exist for TB and are based on IFN-
-release (Interferon- release assays or ‘IGRAs’ for short)(10). Our work suggests that in 
vitro tuberculin-stimulated secretion of IL-2 (effectively an ‘IL-2 release assay’) carries 
particular potential as a predictor of BCG immunotherapy success. If confirmed in larger 
studies in future, its apparent ability to identify 50% of non-responders with 100% 
specificity, even before the beginning of therapy, would be of immediate practical interest.  
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Tables 
 
Table 1: Patient characteristics 
Total number  42 
Age, median (range)  71.2 years (47-89) 
Gender Male 34 
Female 8 
Grade G3 37 (88.1%) 
Carcinoma in situ 18  (42.8%) 
Grade G3 + Carcinoma in situ 13 (30.9%) 
Carcinoma in situ alone 5   (11.9%) 
Stage Ta 12 (28.6%) 
T1 24 (57.1%) 
Lymphovascular invasion 0 
Focality single 30 
multiple 12 
Follow-up time in months 
median (range) 
 16 (15 - 33) 
History of BCG vaccination  24 (57.1%) 
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Table 2: Patient outcomes at 6 months by tumor characteristics. 
 No Recurrence Recurrence p-value 
Number 28 14  
Age, mean (+/-STD) 71 (+/-10.7) 74 (+/-9.2) n.s. 
Male:Female 23:5 11:3 n.s. 
Original Histology 
(Grade) 
G3 
CIS 
Stage 
Ta 
T1 
 
 
24 
14 
 
9 
14 
 
 
82.7% 
50.0% 
 
32.1% 
50.0% 
 
 
13 
4 
 
3 
10 
 
 
92.9% 
28.6% 
 
21.4% 
71.4% 
 
 
n.s. 
n.s. 
 
n.s. 
n.s. 
Multifocal 5 17.8% 7 50.0% n.s. 
History of BCG 
vaccination 
16 57.1% 8 57.1% n.s. 
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Table 3: The effect of tuberculin-induced secreted IL-2 at baseline and patient age on BCG 
immunotherapy outcome 
Parameter p OR 
95% C.I.for OR 
Lower Upper 
IL-2 secretion (Log10) .003 .018 .001 .274 
Age .832 1.009 .932 1.109 
Constant .064 4144.925   
  
A 10-fold increase in IL-2 is associated with a 98.2% reduction in the odds of developing 
recurrence by 6 months. The model provided correct classification of individuals into 
remission and recurrence groups of 87.6%. 
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Figure legends 
 
Figure 1: Tuberculin-inducible IFN-γ and IL-2 correctly may correctly predict outcome of 
intravesical BCG therapy in about two thirds of patients.  
Freshly isolated PBMC were stimulated in vitro with tuberculin for 16 hours. IFN-γ, IL-2 and 
TNF were measured by flow-cytometry using intra-cellular cytokine staining. Alternatively, 
secreted cytokines were measured in the supernatant by electro-chemiluminescence. CD4 
T-cell frequencies are expressed as fractions (0.01=1%) (A) Patients without recurrence of 
cancer at 6 months show significantly higher numbers of cytokine-producing CD4 T-cells in 
response to tuberculin stimulation (left). (B) Secreted IFN- and IL-2 but not TNF seem to 
discriminate better between treatment success and recurrence than the percentage of CD4 
T-cells displaying the corresponding cytokine under (A). (C) ROC analysis for cytokine-
positive CD4 T-cells. The 95% CI for the AUCs were, IFN- 555 – 0.874, IL-
2+ 520-0.922, TNF+ CD4 T-cells: 0.590 – 0.900. (D) ROC analysis for 
secreted cytokines. The 95% CI for the AUCs were, secreted IFN- 0.654 – 0.938, secreted 
IL-2: 0.715-0.989, and secreted TNF: 0.336 – 0.741. (E) Frequencies of CD154+ and IL-17+ 
CD4 T-cells in individuals with and without recurrence at 6 months. A,B,E: Error bars show 
median and interquartile range. 
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Figure 2: Following induction therapy, differences between recurrence-free patients and 
those with recurrence are blurred. (A) Plots show changes between time points one 
(before induction therapy) and two (after induction therapy) in regards to IFN--producing 
tuberculin-inducible CD4 T-cells (left) and secreted IFN- (right). CD4 T-cell frequencies are 
expressed as fractions (0.01=1%)  (B) ROC analysis shows discrimination between the 
outcome groups by age. (C) Scatterplots show associations between age and secreted IFN- 
(left) or IL-2 (right). Patients with remission are shown as empty squares, patients with 
recurrence as filled circles. (D) The scatter plot illustrates how recurrence-free patients and 
those with recurrence may be discriminated based on tuberculin-induced IFN-and IL-2 
secretion prior to therapy using the indicated, tentative thresholds for IFN- and IL-2. Open 
squares indicate recurrence-free survival, filled circles recurrence. A group of seven 
patients with recurrence, whose tuberculin-induced IL-2 levels were below 120 pg/ml are 
highlighted (dotted oval). 
 
 
Figure 3: T-cell polyfunctionality is increased in recurrence-free survivors. (A) Scatter plots 
shows four functional CD4 T-cell subsets that were significantly different between 
recurrence free survival (empty squares) and recurrence (filled circles). Note that CD4 T-cell 
frequencies are expressed as fractions (0.01=1%). Error bars show median and interquartile 
range. (B) ROC curves show the discrimination between the outcome groups based the two 
most promising subsets, producing IFN- and TNF but not IL-17 (95% CI for the AUC: 0.673-
0.932), or, IFN-, TNF and IL-2 (95% CI for the AUC: 0.661-941).  
 
 
 
 
 
 
 



